5/14/2020 8:46:39 AM
TRACON Plan To Present Positive Data From Envafolimab In Pivotal Trial In China
4/14/2020 8:22:39 AM
TRACON Appoints Shahe Garabedian As SVP Of Quality Assurance And Issuance Of An Inducement Award
3/19/2020 8:27:39 AM
TRACON Appoints Saundra Pelletier To Board
10/21/2019 8:10:04 AM
TRACON Enters Stock Purchase Agreement Of Up To $15 Mln With Aspire Capital
7/2/2019 8:10:48 AM
TRACON Pharma Issues Update On Phase 1/2 Trial Of TRC253 In Patients With Metastatic Castrate Resistant Prostate Cancer
4/12/2019 7:10:48 AM
TRACON Pharma Announces Termination Of Phase 3 TAPPAS Trial
3/27/2019 8:16:11 AM
TRACON Pharma Announces TRC105, TRC253 And TRC102 Data Presentations At Upcoming AACR Annual Meeting
1/22/2019 8:36:48 AM
TRACON Pharma Announces Positive Data From Ongoing Phase 1b/2 Trial Of TRC105 In Hepatocellular Carcinoma
12/26/2018 8:36:41 AM
TRACON Announces Submission Of IND Application For TJ4309 For Treatment Of Advanced Solid Tumors
12/21/2018 8:11:54 AM
TRACON Pharma Says Phase 2 TRAXAR Clinical Trial Did Not Meet Primary Endpoint
11/29/2018 2:36:38 AM
TRACON, I-Mab Biopharma Announce Strategic Partnerships For Developing Multiple Immuno-oncology Programs
11/19/2018 8:38:09 AM
TRACON Presents Data From Phase 2 Study Of TRC102 And Temodar
9/10/2018 9:05:20 AM
TRACON Publish Phase 1b Results For TRC105 In Combination With Inlyta In Patients With Advanced Or Metastatic RCC